The incidence and types of adverse reactions to rifampicin (in combination with isoniazid, pyrazinamide, and ethambutol) have been studied in 86 South‐East Asian refugees treated for tuberculosis in Australia. Most patients received daily therapy initially (mean 3.5 months) followed by supervised thrice‐weekly treatment (mean 4.6 months). Minor adverse reactions occurred with similar frequencies during daily (5%) and intermittent (5%) treatment but in no case was modification of rifampicin dosage required. Withdrawal of pyrazinamide was necessary in two patients (2.3%) with clinical hepatitis. Copyright © 1985, Wiley Blackwell. All rights reserved

South‐East Asian refugees Intermittent rifampicin adverse reactions tuberculosis

Australia skin toxicity Prospective Studies human drug intermittent therapy Refugees phenazopyridine amide hyperuricemia intoxication Aged oral drug administration drug efficacy rash Drug Administration Schedule liver toxicity Adolescent Rifampin Tuberculosis, Pulmonary tuberculosis Liver Child, Preschool Hepatitis, Toxic clinical article hepatitis therapy Drug Therapy, Combination Support, Non-U.S. Gov't adult isoniazid drug safety ethambutol Respiratory System nervous system rifampicin pyrazinamide adverse drug reaction Asia, Southeastern Middle Age drug therapy Child